Clinical Trials | December 21, 2025
Takeda posts strong Phase 3 win for oral psoriasis drug
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
Patients with BRCA mutations often face aggressive disease and poor prognosis
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5%/0.3%, of Bausch & Lomb
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
Acetaminophen Injection is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
